Anti-androgenic effects comparison between Cyproterone acetate and Spironolactone in Transgender women: A Randomized Controlled Trial

Phase 4

• Conditions: Total testosterone levelEstradiol levelSex- hormone binding globulin levelProlactin levelLipid profile; Gender dysphoria; Gender identidy distorder; Transgender; Male to Female trans; Spironolactone; Cyproterone acetate; Anti- androgen

• Registration Number: TCTR20190404001
• Lead Sponsor: Ratchadapiseksompotch Fund, Faculty of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-04-04
• Study Completion: 2020-06-16
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: Male
• Target Recruitment: 52

Inclusion Criteria

Gender dysphoria patients (Diagnosed from DSM V)
Male to female transgender
Not underwent orchidectomy
No psychological disease or mental retardation

Exclusion Criteria

Anti-androgen usage 3 months prior to inclusion date
History of active liver or kidney disease
Diabetes type I, II
Abnormal liver function test, Kidney function
High serum potassium
High prolactin level

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Testosterone level 3 months after intervention ECLIA of total testosterone level

Secondary Outcome Measures

Name	Time	Method
Physical and Metabolic changes 3 months after intervention Physical examination, Metabolic profile parameters